Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

  • In development
  • GID-TA11340
  • Expected publication date: TBC

NICE has paused the evaluation of durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317] because the company and NHSE have commenced commercial discussions.

NICE has been made aware of some inconsistencies regarding the appeal process for this appraisal. As a result, the publication of final guidance will be delayed and consultees will have the opportunity to submit appeals until 5pm Thursday 10 July.